Literature DB >> 11558905

The T911C (F304S) substitution in the human ALG6 gene is a common polymorphism and not a causal mutation of CDG-Ic.

S Vuillaumier-Barrot1, C Le Bizec, G Durand, N Seta.   

Abstract

A T911C (F304S) substitution in the ALG6 gene involved in congenital disorder of glycosylation type Ic (OMIM 603147) has been described. However, whether the F304S substitution is a common polymorphism or a causal mutation remains unclear. We screened for the T911C substitution in the ALG6 gene in 54 unrelated healthy French individuals. We developed a restriction fragment length polymorphism assay with a mutagenic primer introducing a diagnostic DdeI restriction site. We found 23 heterozygotes (42.6%) and 3 homozygous individuals (5.5%). This result indicates that T911C is a common polymorphism with an allele frequency of 27% in a French population and not a causal mutation of congenital disorder of glycosylation type Ic.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11558905     DOI: 10.1007/s100380170038

Source DB:  PubMed          Journal:  J Hum Genet        ISSN: 1434-5161            Impact factor:   3.172


  5 in total

1.  Frequency Determination of α-1,3 Glucosyltransferase p.Y131H and p.F304S Polymorphisms in the Croatian Population Revealed Five Novel Single Nucleotide Polymorphisms in the hALG6 Gene.

Authors:  Sandra Supraha Goreta; Sanja Dabelic; Dinko Pavlinic; Gordan Lauc; Jerka Dumic
Journal:  Genet Test Mol Biomarkers       Date:  2011-09-07

2.  ALG6-CDG: a recognizable phenotype with epilepsy, proximal muscle weakness, ataxia and behavioral and limb anomalies.

Authors:  Eva Morava; Vera Tiemes; Christian Thiel; Nathalie Seta; Pascale de Lonlay; Hans de Klerk; Margot Mulder; Estela Rubio-Gozalbo; Gepke Visser; Peter van Hasselt; Dafne D G Horovitz; Carolina Fischinger Moura de Souza; Ida V D Schwartz; Andrew Green; Mohammed Al-Owain; Graciella Uziel; Sabine Sigaudy; Brigitte Chabrol; Franc-Jan van Spronsen; Martin Steinert; Eleni Komini; Donald Wurm; Andrea Bevot; Addelkarim Ayadi; Karin Huijben; Marli Dercksen; Peter Witters; Jaak Jaeken; Gert Matthijs; Dirk J Lefeber; Ron A Wevers
Journal:  J Inherit Metab Dis       Date:  2016-06-10       Impact factor: 4.982

3.  The Analysis of Variants in the General Population Reveals That PMM2 Is Extremely Tolerant to Missense Mutations and That Diagnosis of PMM2-CDG Can Benefit from the Identification of Modifiers.

Authors:  Valentina Citro; Chiara Cimmaruta; Maria Monticelli; Guglielmo Riccio; Bruno Hay Mele; Maria Vittoria Cubellis; Giuseppina Andreotti
Journal:  Int J Mol Sci       Date:  2018-07-30       Impact factor: 5.923

Review 4.  Insights into complexity of congenital disorders of glycosylation.

Authors:  Sandra Supraha Goreta; Sanja Dabelic; Jerka Dumic
Journal:  Biochem Med (Zagreb)       Date:  2012       Impact factor: 2.313

5.  A case of fatal Type I congenital disorders of glycosylation (CDG I) associated with low dehydrodolichol diphosphate synthase (DHDDS) activity.

Authors:  S Sabry; S Vuillaumier-Barrot; E Mintet; M Fasseu; V Valayannopoulos; D Héron; N Dorison; C Mignot; N Seta; I Chantret; T Dupré; S E H Moore
Journal:  Orphanet J Rare Dis       Date:  2016-06-24       Impact factor: 4.123

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.